Obsessive-Compulsive Disorder (OCD)
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
EppendorfGermany - Hamburg
1 program1
Exposure therapy with pharmacological facilitationPhase 21 trial
Active Trials
Angeles TherapeuticsCA - Los Angeles
1 programIntensive Cognitive Behavioral TherapyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
EppendorfExposure therapy with pharmacological facilitation
MedtronicReclaim™ DBS Therapy
Angeles TherapeuticsIntensive Cognitive Behavioral Therapy
Clinical Trials (3)
Total enrollment: 185 patients across 3 trials
Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder
Start: Sep 2013Est. completion: Dec 201860 patients
Phase 2Unknown
DBS for Obsessive-Compulsive Disorder
Start: Jul 2024Est. completion: Jan 203050 patients
N/ARecruiting
Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder
Start: Jul 2011Est. completion: Jun 201575 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 185 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.